BioSpace News Archive

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced updated results from its Phase 1b/2 clinical trial of ciforadenant, an adenosine A2A receptor antagonist, in patients with metastatic castration resistant prostate cancer (mCRPC).

Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it has filed a 510(k) application for US FDA clearance for its next generation, advanced ECG analysis software.

While 65% say they don’t have access to a COVID-19 test kit, only 9% are very concerned; verbatim remarks citing media hype, emphasize the greater concern is flu

Centene Corporation (NYSE: CNC) today issued a reminder that it will provide its consolidated 2020 annual guidance, including WellCare Health Plans, Inc. (WellCare), after the close of trading on Tuesday, March 3, 2020, and host a conference call on Wednesday, March 4, 2020 at approximately 8:30 a.m. (Eastern Time)

InnerScope, as a Preferred Seller on Sears.com with its Hearing Products, now offers a complete line of Doctor-Formulated “Nutrition for the Ears” Dietary Hearing and Tinnitus Supplements on Sears.com

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in research-driven, pharmaceutical quality cannabis extraction, distillation and derivative product production, announced it will release its audited financial results, within the timelines required by TSX issuers, for the three and twelve months ended December 31, 2019

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the appointment of Scott Applebaum as Chief Legal and Compliance Officer and Senior Vice President of Regulatory Affairs

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today reported business highlights and financial results for the fourth quarter and year ended December 31, 2019.

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, intends to report operational highlights and financial results for the year ended December 31, 2019 on Thursday, February 20, 2020,

Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its fourth quarter and full year 2019 financial and operating results and provide a business update after market close on Monday, February 24, 2020